Nanobiotix
Public companyFR1 field
Where it works
| Technology | ||
|---|---|---|
| NanotechnologyDevelops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900. | Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900. | nanobiotix.com |
Events
| Date | Event | ||
|---|---|---|---|
| May 21, 2026 | Nanobiotix prices an oversubscribed EUR 85M global offeringsec.gov· Funding· Nanotechnology | Nanotechnology | Funding |
| Mar 30, 2026 | First randomized Phase 2 data for JNJ-1900 in stage 3 lung cancersec.gov· Milestone· Nanotechnology | Nanotechnology | Milestone |
| Jul 7, 2025 | European regulators reclassify NBTXR3 from device to medicinal productsec.gov· Policy· Nanotechnology | Nanotechnology | Policy |
| Mar 17, 2025 | Nanobiotix amends its NBTXR3 licensing deal with Johnson & Johnsonsec.gov· Deal· Nanotechnology | Nanotechnology | Deal |
| May 14, 2024 | FDA accepts protocol for Phase 2 NBTXR3 study in stage 3 lung cancersec.gov· Milestone· Nanotechnology | Nanotechnology | Milestone |
Funding
About
- Source
- nanobiotix.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | NanobiotixCompany in Nanotechnology: Joined a field, Develops NBTXR3, radiation-enhancing nanoparticles licensed to Johnson & Johnson as JNJ-1900. | seed | nanobiotix.com |
| Sep 25, 2026 | NanobiotixCompany: Added | seed | nanobiotix.com |